ArticlePathogens (Basel, Switzerland)2020
Imidocarb Dipropionate Lacks Efficacy against
Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Treatment Efficacy of Imidocarb Dipropionate in Saanen Goats Experimentally Infected withPathogens (Basel, Switzerland) · 2026Article
- Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi.Parasites & vectors · 2026Article
- A high-quality genome sequence of the equine apicomplexan hemoparasiteMicrobiology resource announcements · 2026Article
- First molecular detection ofFrontiers in veterinary science · 2026Article
- Molecular Prevalence and Genotypic Diversity ofVeterinary sciences · 2025Article
- Persistence and Transmission Dynamics ofPathogens (Basel, Switzerland) · 2025Article
- Treatment evaluation using ultrasonographic scanning of the spleen in Arabian horses affected by babesiosis.Open veterinary journal · 2025Article
- Epidemiology and genetic diversity of Theileria equi and Babesia caballi in draft horses in the Distrito Federal, Brazil.Tropical animal health and production · 2025Article
- Molecular Diagnosis and Identification of Equine Piroplasms: Challenges and Insights from a Study in Northern Italy.Animals : an open access journal from MDPI · 2025Article
- Article
- The Combination of Buparvaquone and ELQ316 Exhibit a Stronger Effect than ELQ316 and Imidocarb AgainstPharmaceutics · 2024Article
- Transient efficacy of buparvaquone against Theileria haneyi in chronically infected horses.Parasites & vectors · 2024Article
- Current vaccines, experimental immunization trials, and new perspectives to control selected vector borne blood parasites of veterinary importance.Frontiers in veterinary science · 2024Review
- Expression of IL-10 and TGF-β1 in horses experimentally infected withFrontiers in immunology · 2024Article
- Revisiting the genotypes ofFrontiers in veterinary science · 2024Article
- Comparative efficacy of buparvaquone and imidocarb in inhibiting theFrontiers in pharmacology · 2024Article
- New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths.Frontiers in veterinary science · 2024Review
- Development and evaluation of specific polymerase chain reaction assays for detecting Theileria equi genotypes.Parasites & vectors · 2023Article
- Impact of Equine and Camel Piroplasmosis in Egypt: How Much Do We Know about the Current Situation?Pathogens (Basel, Switzerland) · 2023Review
- Development of a Real-Time Quantitative PCR Based on a TaqMan-MGB Probe for the Rapid Detection ofMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
Control of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.